Lonza’s End-to-End Offering for Best-in-Class Targeted Therapies Based on GlycoConnect® & HydraSpace® Technologies

• Exploring how GlycoConnect® and HydraSpace® technologies enable ADCs with best-in-class therapeutic potential
• Sharing clinical development insights on the rapidly advancing pipeline of GlycoConnect® ADCs by partners
• GlycoConnect® technology expansion for dual-payload ADCs with compelling in vivo data

Speakers:

Marcel Scheepstra

Director, Organic chemistry, Bioconjugates R&D

Lonza Advanced Synthesis